FOR THE THIRD QUARTER OF 2024 (Q3 2024), both of the nation’s largest publicly traded laboratories—Labcorp and Quest Diagnostics—reported growing revenue, more emphasis on specialty testing and advanced diagnostics, as well as progress with acquisitions and partnerships. LABCORP: Grows Q3 Revenue 7.4%, Advances Acquisitions Labcorp, Burlington, N.C., shared these Q3 2024 and nine-month financial results […]
Insights from Q3 2024 Earnings Calls Point to a More Robust Lab Market
During Q3, both Labcorp and Quest Diagnostics boosted revenue, closed acquisitions, and added tests
- By Robert Michel
- > From the Volume XXXI No. 15 - November 4, 2024 Issue
- Tags: AD-Detect, Adam Schecter, Allina Health, Alzheimer’s, autoimmune disorder, Ballad Health, Biopharma, COVID testing, COVID-19, diagnostics, Glenn Eisenberg, Jim Davis, lab intelligence, LabCorp, Labcorp OnDemand, LifeLabs, medicare clinical laboratory fee schedule, Naples Comprehensive Healthcare, OhioHealth, PAMA, pandemic, Quest Diagnostics, Questhealth.com, SALSA, Sam Samad, Saving Access to Laboratory Services Act, Walgreens
